CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CEP104 (ImmuneEditome ID:9731)

1. Gene summary of enriched editing regions for CEP104

check button Gene summary
Gene informationGene symbol

CEP104

Gene ID

9731

GeneSynonymsCFAP256|GlyBP|JBTS25|KIAA0562|MRT77|ROC22
GeneCytomap

1p36.32

GeneTypeprotein-coding
GeneDescriptioncentrosomal protein of 104 kDa|centrosomal protein 104kDa
GeneModificationdate20230329
UniprotIDO60308;A0A6Q8PG89;A0A6Q8PFR4;A0A6Q8PGB3;A0A6Q8PHR0;A0A6Q8PH69;A0A6Q8PHE1;A0A6Q8PGQ7;A0A6Q8PGF0;A0A6Q8PH38;Q5SR27;J3QLL3;A0A6Q8PH14
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:3812546-3813860:-ENST00000378230.6ENSG00000116198.11CEP104UTR3AluSx3,AluSx,(AT)nchr1:3812546-3813860:-.alignment
chr1:3826854-3827501:-ENST00000378230.6ENSG00000116198.11CEP104intronicAluJbchr1:3826854-3827501:-.alignment
chr1:3826854-3827501:-ENST00000438539.4ENSG00000116198.11CEP104intronicAluJbchr1:3826854-3827501:-.alignment
chr1:3826854-3827501:-ENST00000461667.1ENSG00000116198.11CEP104intronicAluJbchr1:3826854-3827501:-.alignment


Top

2. Tumor-specific enriched editing regions for CEP104


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:3812546-3813860:-BRCAEER8.3056e-08image
ENSG00000116198.11,CEP104BRCAEAG9.8623e-06image
chr1:3812546-3813860:-KICHEER3.4166e-04image
ENSG00000116198.11,CEP104KICHEAG4.4453e-04image
chr1:3812546-3813860:-KIRPEER1.3015e-12image
ENSG00000116198.11,CEP104KIRPEAG4.6601e-12image
chr1:3812546-3813860:-LUSCEER5.3619e-11image
ENSG00000116198.11,CEP104LUSCEAG7.0679e-09image
chr1:3812546-3813860:-PRADEER7.2514e-05image
ENSG00000116198.11,CEP104PRADEAG1.3820e-04image
chr1:3812546-3813860:-UCECEER6.8272e-03image
ENSG00000116198.11,CEP104UCECEAG1.7899e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000116198.11,CEP104LUADPathEAG2.6851e-022.3865e-020.1076image
ENSG00000116198.11,CEP104SKCMPathEAG2.5040e-033.8342e-020.1132image
chr1:3812546-3813860:-SKCMPathEER3.7076e-033.5743e-020.1148image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000116198.11,CEP104ESCAEAG9.9496e-033.6674e-027.6004e-02image

Top

3. Enriched editing regions and immune related genes for CEP104


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:3812546-3813860:-GBMEERENSG00000198898,CAPZA20.34422.2329e-031.0050e-080.4414imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;LIN28A;NONO;NOP58;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;YWHAGNAMacrophages_M0GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:3812546-3813860:-GBMEERENSG00000223822,EEF1A1P10.32843.7759e-035.7854e-080.4202imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_MYC_TARGETS_V1
chr1:3812546-3813860:-GBMEERENSG00000223529,EEF1A1P80.31466.0749e-039.3512e-090.4422imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr1:3812546-3813860:-GBMEERENSG00000215414,PSMA6P10.30827.9246e-032.4875e-070.4014imageNNPSMA6P1T_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr1:3812546-3813860:-GBMEERENSG00000185839,RP4-592A1.20.29341.2308e-021.7629e-070.4059imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:3812546-3813860:-GBMEERENSG00000259612,EEF1A1P220.28891.3401e-021.8226e-070.4055imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr1:3812546-3813860:-GBMEERENSG00000243498,UBA52P50.29111.3803e-021.3403e-070.4095imageNNNAGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:3812546-3813860:-GBMEERENSG00000223668,EEF1A1P240.28601.5070e-021.8009e-070.4056imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr1:3812546-3813860:-GBMEERENSG00000155366,RHOC0.28031.9541e-027.9989e-080.4161imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;NONO;NOP58;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;YWHAGNAT_cells_gamma_deltaGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:3812546-3813860:-GBMEERENSG00000214784,AC010468.10.27701.9930e-021.2663e-070.4102imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_APICAL_JUNCTION

More results



Top

4. Enriched editing regions and immune related splicing for CEP104


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:3812546-3813860:-
GBMEERIRENSG00000142102.11chr11292885:293502:293593:293727-0.31969.2486e-031.0120e-06-0.4091imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;NONO;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TROVE2;YWHAGATHL1T_cells_CD8GSVA_HALLMARK_ADIPOGENESIS
chr1:3812546-3813860:-
GBMEERIRENSG00000072195.10chr2219443107:219443150:219444024:219444059-0.26653.8683e-023.5003e-06-0.4060imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;NOP58;PTBP1;RBFOX2;SLTM;SRSF1;TAF15;TROVE2;YWHAGNAPlasma_cellsGSVA_HALLMARK_ADIPOGENESIS
chr1:3812546-3813860:-
GBMEERIRENSG00000050426.11chr1251048312:51048371:51049033:51049185-0.25973.8795e-021.3981e-06-0.4176imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;LIN28A;NONO;NOP58;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;YWHAGNAT_cells_follicular_helperGSVA_HALLMARK_GLYCOLYSIS
ENSG00000116198.11,CEP104
GBMEAGIRENSG00000119723.11chr1473958146:73958277:73958970:73959078-0.47982.2349e-052.5682e-07-0.4021imageNADAR;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;ZC3H7B;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000116198.11,CEP104
GBMEAGIRENSG00000182149.16chr1671923287:71923380:71924772:71924817-0.30521.9253e-029.9334e-07-0.4011imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YTHDF2;ZC3H7B;ZNF184NANK_cells_restingGSVA_HALLMARK_PEROXISOME
ENSG00000116198.11,CEP104
GBMEAGIRENSG00000142102.11chr11292885:293502:293593:293727-0.31991.0644e-021.4236e-06-0.4040imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184ATHL1T_cells_CD8GSVA_HALLMARK_ADIPOGENESIS
chr1:3812546-3813860:-
GBMEERIRENSG00000119723.11chr1473958146:73958277:73958970:73959078-0.48261.8414e-052.1144e-07-0.4047imageNDGCR8;FXR1;HNRNPC;HNRNPM;HNRNPU;IGF2BP2;KHSRP;NONO;NOP58;PTBP1;RBFOX2;SAFB2;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000116198.11,CEP104
GBMEAGIRENSG00000050426.11chr1251048312:51048371:51049033:51049185-0.27432.5559e-025.0719e-07-0.4331imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_GLYCOLYSIS
chr1:3812546-3813860:-
GBMEERIRENSG00000111237.14chr12110498819:110498859:110499534:110499546-0.26273.3908e-028.8271e-06-0.4045imageNDGCR8;FXR1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;KHSRP;LIN28A;NONO;NOP58;PTBP1;RBFOX2;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;YWHAGNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
ENSG00000116198.11,CEP104
GBMEAGIRENSG00000072195.10chr2219443107:219443150:219444024:219444059-0.27752.9740e-022.6586e-06-0.4105imageNACIN1;ADAR;AIFM1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SLTM;SMNDC1;SRSF1;SRSF10;TAF15;TARDBP;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAPlasma_cellsGSVA_HALLMARK_ADIPOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for CEP104


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:3812546-3813860:-BLCAEERT_cells_gamma_delta2.7037e-02-0.1285image
ENSG00000116198.11,CEP104BLCAEAGT_cells_gamma_delta3.1061e-02-0.1247image
chr1:3812546-3813860:-BRCAEERMacrophages_M21.7857e-03-0.0979image
ENSG00000116198.11,CEP104BRCAEAGMacrophages_M21.6447e-03-0.0986image
chr1:3812546-3813860:-CESCEERNeutrophils2.9025e-020.1378image
chr1:3812546-3813860:-CHOLEERPlasma_cells1.0184e-020.5245image
chr1:3812546-3813860:-COADEERDendritic_cells_resting4.7921e-02-0.1306image
chr1:3812546-3813860:-DLBCEERB_cells_naive1.5816e-02-0.5079image
ENSG00000116198.11,CEP104DLBCEAGB_cells_naive1.5816e-02-0.5079image
chr1:3812546-3813860:-ESCAEERDendritic_cells_activated4.7364e-03-0.2341image
ENSG00000116198.11,CEP104ESCAEAGDendritic_cells_activated7.3539e-03-0.2202image
chr1:3812546-3813860:-HNSCEERNeutrophils8.6115e-030.1364image
ENSG00000116198.11,CEP104HNSCEAGNeutrophils3.6939e-030.1500image
chr1:3812546-3813860:-KICHEERMacrophages_M09.3780e-040.4163image
ENSG00000116198.11,CEP104KICHEAGMacrophages_M02.4492e-030.3841image
chr1:3812546-3813860:-KIRCEERT_cells_follicular_helper3.1156e-030.1541image
ENSG00000116198.11,CEP104KIRCEAGT_cells_follicular_helper2.4879e-020.1171image
chr1:3812546-3813860:-KIRPEERNeutrophils3.5290e-020.1365image
ENSG00000116198.11,CEP104KIRPEAGNeutrophils4.3202e-020.1309image
ENSG00000116198.11,CEP104LAMLEAGMacrophages_M12.2788e-02-0.4144image
chr1:3812546-3813860:-LGGEERMacrophages_M13.6722e-02-0.0921image
ENSG00000116198.11,CEP104LGGEAGMacrophages_M11.5755e-02-0.1063image
chr1:3812546-3813860:-LIHCEERPlasma_cells7.0586e-030.1804image
ENSG00000116198.11,CEP104LIHCEAGB_cells_naive2.0748e-020.1541image
chr1:3812546-3813860:-LUADEERT_cells_CD4_memory_activated1.0386e-020.1221image
ENSG00000116198.11,CEP104LUADEAGT_cells_CD81.1208e-020.1203image
chr1:3812546-3813860:-LUSCEERNK_cells_activated3.1241e-02-0.1079image
ENSG00000116198.11,CEP104LUSCEAGNK_cells_activated2.4426e-02-0.1117image
chr1:3812546-3813860:-MESOEERMacrophages_M23.8330e-030.3565image
ENSG00000116198.11,CEP104MESOEAGMacrophages_M29.8478e-030.3180image
chr1:3812546-3813860:-OVEERT_cells_CD4_memory_activated2.3229e-030.1957image
ENSG00000116198.11,CEP104OVEAGT_cells_CD4_memory_activated2.6928e-030.1925image
chr1:3812546-3813860:-PAADEERNK_cells_resting1.0688e-020.2058image
ENSG00000116198.11,CEP104PAADEAGNK_cells_resting8.6714e-030.2115image
chr1:3812546-3813860:-PCPGEERNK_cells_resting1.3200e-02-0.2000image
ENSG00000116198.11,CEP104PCPGEAGNK_cells_resting1.4120e-02-0.1981image
chr1:3812546-3813860:-PRADEEREosinophils8.4377e-030.1222image
ENSG00000116198.11,CEP104PRADEAGEosinophils6.1397e-030.1270image
chr1:3812546-3813860:-READEERPlasma_cells3.8811e-020.2273image
ENSG00000116198.11,CEP104READEAGPlasma_cells4.9419e-020.2164image
ENSG00000116198.11,CEP104SARCEAGMacrophages_M23.7458e-020.1398image
chr1:3812546-3813860:-SKCMEERMacrophages_M04.2388e-020.1034image
ENSG00000116198.11,CEP104SKCMEAGMacrophages_M03.1818e-020.1092image
ENSG00000116198.11,CEP104STADEAGPlasma_cells4.7337e-020.1176image
chr1:3812546-3813860:-THCAEERT_cells_CD4_memory_activated1.7771e-060.2152image
ENSG00000116198.11,CEP104THCAEAGT_cells_CD4_memory_activated3.4105e-050.1872image
chr1:3812546-3813860:-THYMEERB_cells_memory1.9542e-02-0.2405image
ENSG00000116198.11,CEP104THYMEAGB_cells_memory1.7602e-02-0.2444image
chr1:3812546-3813860:-UVMEERMast_cells_resting8.2870e-030.3731image
ENSG00000116198.11,CEP104UVMEAGMast_cells_resting8.2870e-030.3731image


Top

6. Enriched editing regions and immune gene sets for CEP104


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000116198.11,CEP104BRCAEAG3.7829e-040.11131.6262e-020.07531.2051e-030.10145.5342e-030.0869image
chr1:3812546-3813860:-BRCAEER2.6556e-040.11422.5808e-030.09451.0564e-030.10268.3672e-030.0827image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:3812546-3813860:-BLCAGSVA_HALLMARK_MYC_TARGETS_V1EER4.8398e-02-0.1148image
ENSG00000116198.11,CEP104BLCAGSVA_HALLMARK_MYC_TARGETS_V1EAG2.4892e-02-0.1297image
ENSG00000116198.11,CEP104BRCAGSVA_HALLMARK_GLYCOLYSISEAG1.0437e-040.1214image
chr1:3812546-3813860:-BRCAGSVA_HALLMARK_GLYCOLYSISEER2.8421e-050.1310image
ENSG00000116198.11,CEP104CESCGSVA_HALLMARK_GLYCOLYSISEAG2.2694e-020.1438image
chr1:3812546-3813860:-CESCGSVA_HALLMARK_GLYCOLYSISEER1.9580e-020.1473image
ENSG00000116198.11,CEP104CHOLGSVA_HALLMARK_DNA_REPAIREAG2.4467e-03-0.6005image
chr1:3812546-3813860:-CHOLGSVA_HALLMARK_DNA_REPAIREER6.8915e-03-0.5472image
ENSG00000116198.11,CEP104COADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2526e-020.1644image
chr1:3812546-3813860:-COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.0649e-020.1681image
ENSG00000116198.11,CEP104ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.6324e-020.1978image
chr1:3812546-3813860:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7612e-02-0.1836image
chr1:3812546-3813860:-GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.5522e-060.3599image
ENSG00000116198.11,CEP104GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG4.4042e-060.3604image
ENSG00000116198.11,CEP104HNSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG9.2550e-030.1346image
chr1:3812546-3813860:-HNSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.2445e-020.1298image
chr1:3812546-3813860:-KICHGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4172e-02-0.3152image
ENSG00000116198.11,CEP104KICHGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG9.2008e-03-0.3336image
ENSG00000116198.11,CEP104KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG1.0932e-02-0.1327image
chr1:3812546-3813860:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER5.4778e-03-0.1449image
ENSG00000116198.11,CEP104KIRPGSVA_HALLMARK_MYC_TARGETS_V1EAG1.5945e-020.1558image
chr1:3812546-3813860:-KIRPGSVA_HALLMARK_MYC_TARGETS_V2EER1.3921e-020.1592image
ENSG00000116198.11,CEP104LAMLGSVA_HALLMARK_KRAS_SIGNALING_UPEAG1.2861e-020.4488image
chr1:3812546-3813860:-LGGGSVA_HALLMARK_NOTCH_SIGNALINGEER8.4453e-05-0.1724image
ENSG00000116198.11,CEP104LGGGSVA_HALLMARK_NOTCH_SIGNALINGEAG5.5630e-05-0.1766image
ENSG00000116198.11,CEP104LUADGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.1933e-030.1450image
chr1:3812546-3813860:-LUADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER4.2186e-030.1362image
chr1:3812546-3813860:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER9.5827e-03-0.1296image
ENSG00000116198.11,CEP104LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.6206e-02-0.1103image
chr1:3812546-3813860:-MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.6036e-04-0.4547image
ENSG00000116198.11,CEP104MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEAG9.4234e-05-0.4653image
ENSG00000116198.11,CEP104OVGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.8296e-040.2319image
chr1:3812546-3813860:-OVGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.2407e-040.2302image
ENSG00000116198.11,CEP104PAADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5152e-03-0.2543image
chr1:3812546-3813860:-PAADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6719e-03-0.2520image
chr1:3812546-3813860:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER4.3996e-06-0.2113image
ENSG00000116198.11,CEP104PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.9366e-05-0.1896image
ENSG00000116198.11,CEP104READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.7988e-02-0.2282image
ENSG00000116198.11,CEP104SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.7087e-03-0.2004image
chr1:3812546-3813860:-SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.8660e-03-0.1992image
chr1:3812546-3813860:-SKCMGSVA_HALLMARK_GLYCOLYSISEER4.7591e-030.1434image
ENSG00000116198.11,CEP104SKCMGSVA_HALLMARK_GLYCOLYSISEAG3.7346e-030.1471image
chr1:3812546-3813860:-STADGSVA_HALLMARK_SPERMATOGENESISEER2.9291e-02-0.1303image
ENSG00000116198.11,CEP104STADGSVA_HALLMARK_SPERMATOGENESISEAG2.5753e-02-0.1321image
chr1:3812546-3813860:-TGCTGSVA_HALLMARK_UV_RESPONSE_DNEER1.1758e-03-0.3564image
ENSG00000116198.11,CEP104TGCTGSVA_HALLMARK_UV_RESPONSE_DNEAG9.3124e-04-0.3631image
chr1:3812546-3813860:-THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7490e-020.1080image
chr1:3812546-3813860:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.7376e-020.2142image
ENSG00000116198.11,CEP104UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.7660e-020.1970image
ENSG00000116198.11,CEP104UCSGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1876e-02-0.4149image
chr1:3812546-3813860:-UCSGSVA_HALLMARK_KRAS_SIGNALING_DNEER7.4921e-03-0.4384image
ENSG00000116198.11,CEP104UVMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.1369e-030.4136image
chr1:3812546-3813860:-UVMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.1369e-030.4136image


Top

7. Enriched editing regions and drugs for CEP104


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000116198.11,CEP104ACCBIBW2992EAG4.3681e-020.2614image
chr1:3812546-3813860:-ACCAUY922EER4.6118e-02-0.2585image
chr1:3812546-3813860:-BLCACyclopamineEER1.7122e-020.1385image
ENSG00000116198.11,CEP104BLCAEtoposideEAG9.9338e-030.1489image
chr1:3812546-3813860:-BRCACyclopamineEER1.8668e-04-0.1174image
ENSG00000116198.11,CEP104BRCADasatinibEAG3.1938e-04-0.1129image
chr1:3812546-3813860:-CESCA.770041EER6.1586e-03-0.1725image
ENSG00000116198.11,CEP104CESCA.770041EAG2.9011e-02-0.1378image
ENSG00000116198.11,CEP104CHOLMG.132EAG1.9392e-020.4836image
chr1:3812546-3813860:-CHOLBryostatin.1EER1.6065e-020.4961image
chr1:3812546-3813860:-COADBX.795EER1.5865e-02-0.1589image
ENSG00000116198.11,CEP104COADBX.795EAG2.5827e-02-0.1470image
ENSG00000116198.11,CEP104DLBCElesclomolEAG1.1805e-020.5266image
chr1:3812546-3813860:-DLBCElesclomolEER1.1805e-020.5266image
ENSG00000116198.11,CEP104ESCABAY.61.3606EAG2.7424e-02-0.1819image
chr1:3812546-3813860:-ESCACGP.082996EER2.7742e-040.2986image
ENSG00000116198.11,CEP104GBMBIRB.0796EAG4.1056e-060.3615image
chr1:3812546-3813860:-GBMBIRB.0796EER4.0583e-060.3617image
ENSG00000116198.11,CEP104HNSCFTI.277EAG5.1393e-03-0.1446image
chr1:3812546-3813860:-HNSCGefitinibEER3.6158e-03-0.1513image
chr1:3812546-3813860:-KICHAZD6482EER2.3004e-020.2932image
ENSG00000116198.11,CEP104KICHAZD6482EAG2.0964e-020.2975image
ENSG00000116198.11,CEP104KIRCBAY.61.3606EAG7.9733e-030.1383image
chr1:3812546-3813860:-KIRCBortezomibEER4.1921e-03-0.1493image
ENSG00000116198.11,CEP104KIRPCCT007093EAG1.0161e-020.1660image
chr1:3812546-3813860:-KIRPCCT007093EER6.8730e-030.1748image
chr1:3812546-3813860:-LGGCamptothecinEER1.3567e-05-0.1904image
ENSG00000116198.11,CEP104LGGCamptothecinEAG5.9052e-06-0.1981image
chr1:3812546-3813860:-LIHCAP.24534EER2.8076e-02-0.1474image
ENSG00000116198.11,CEP104LIHCAP.24534EAG2.4383e-02-0.1501image
ENSG00000116198.11,CEP104LUADFH535EAG1.1902e-030.1533image
chr1:3812546-3813860:-LUADFH535EER1.1528e-040.1828image
chr1:3812546-3813860:-LUSCMG.132EER6.6755e-03-0.1358image
ENSG00000116198.11,CEP104LUSCMG.132EAG1.9219e-02-0.1163image
chr1:3812546-3813860:-MESOGemcitabineEER1.9515e-02-0.2913image
ENSG00000116198.11,CEP104MESOBIRB.0796EAG1.8083e-02-0.2924image
ENSG00000116198.11,CEP104OVAP.24534EAG1.8689e-02-0.1514image
chr1:3812546-3813860:-OVAP.24534EER3.5731e-02-0.1356image
ENSG00000116198.11,CEP104PAADCCT007093EAG2.7068e-020.1787image
chr1:3812546-3813860:-PAADAZD6482EER2.0049e-020.1910image
chr1:3812546-3813860:-PCPGGW.441756EER1.8219e-02-0.1907image
ENSG00000116198.11,CEP104PCPGGW.441756EAG2.2623e-02-0.1842image
ENSG00000116198.11,CEP104PRADCamptothecinEAG2.3571e-04-0.1699image
chr1:3812546-3813860:-PRADCamptothecinEER1.2643e-04-0.1770image
ENSG00000116198.11,CEP104READABT.263EAG3.0739e-020.2388image
chr1:3812546-3813860:-READABT.263EER3.5558e-020.2325image
chr1:3812546-3813860:-SARCCytarabineEER4.5048e-03-0.1900image
ENSG00000116198.11,CEP104SARCCytarabineEAG1.5516e-03-0.2112image
ENSG00000116198.11,CEP104SKCMBryostatin.1EAG6.6582e-03-0.1377image
chr1:3812546-3813860:-SKCMBryostatin.1EER1.2992e-02-0.1263image
ENSG00000116198.11,CEP104STADAZD6244EAG1.1533e-02-0.1494image
chr1:3812546-3813860:-STADLFM.A13EER3.5352e-02-0.1258image
ENSG00000116198.11,CEP104TGCTAZD8055EAG1.3774e-03-0.3517image
chr1:3812546-3813860:-TGCTAZD8055EER1.5045e-03-0.3491image
ENSG00000116198.11,CEP104THCACamptothecinEAG2.0567e-07-0.2334image
chr1:3812546-3813860:-THCAGSK269962AEER3.6548e-07-0.2289image
chr1:3812546-3813860:-THYMDocetaxelEER2.6525e-03-0.3066image
ENSG00000116198.11,CEP104THYMDocetaxelEAG2.7093e-03-0.3060image
chr1:3812546-3813860:-UCECEtoposideEER3.6295e-02-0.1890image
chr1:3812546-3813860:-UCSAKT.inhibitor.VIIIEER1.0804e-02-0.4198image
ENSG00000116198.11,CEP104UCSAKT.inhibitor.VIIIEAG9.8666e-03-0.4245image
chr1:3812546-3813860:-UVMLFM.A13EER1.7138e-02-0.3391image
ENSG00000116198.11,CEP104UVMLFM.A13EAG1.7138e-02-0.3391image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType